Home › Research › TREM2 and immune genetics
TYROBP in Alzheimer's disease
Ma J, Jiang T, Tan L, Yu JT.. Molecular neurobiology, 2014-07-23
Topic: Amyloid, tau and blood-test diagnosis
Recently, studies have provided convincing data that TYRO protein tyrosine kinase-binding protein (TYROBP), a key regulator in immune systems, is significantly upregulated in the brain of patients with Alzheimer's disease (AD). TYROBP acts as a signaling adaptor protein for numerous cell surface receptors, playing important roles in signal transduction in dendritic cells, osteoclasts, macrophages, and microglia. Although several TYROBP-related cell surface receptors including triggering receptor expressed on myeloid 2 (TREM2), signal regulatory protein β1 (SIRPβ1), and complement receptor 3 (CR3) were found to participate in the pathogenesis of AD, the role of TYROBP in AD still remains elusive.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ma, J., Jiang, T., Tan, L., & Yu, J. T. (2015). TYROBP in Alzheimer's disease. Molecular neurobiology. https://doi.org/10.1007/s12035-014-8811-9
Vancouver
Ma J, Jiang T, Tan L, Yu JT. TYROBP in Alzheimer's disease. Molecular neurobiology. 2015. doi:10.1007/s12035-014-8811-9. PMID: 25052481.
BibTeX
@article{ma2015-25052481,
author = {Ma, J. and Jiang, T. and Tan, L. and Yu, J. T.},
title = {{TYROBP in Alzheimer's disease}},
journal = {Molecular neurobiology},
year = {2015},
doi = {10.1007/s12035-014-8811-9},
pmid = {25052481},
url = {https://doi.org/10.1007/s12035-014-8811-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- TYROBP acts as a signaling adaptor protein for numerous cell surface receptors, playing important roles in signal transduction in dendritic cells, osteoclasts, macrophages, and microglia.
- Although several TYROBP-related cell surface receptors including triggering receptor expressed on myeloid 2 (TREM2), signal regulatory protein β1 (SIRPβ1), and complement receptor 3 (CR3) were found to participate in the pathogenesis of AD, the role of TYROBP in AD still remains elusive.
- Emerging piece of evidence has demonstrated that TYROBP could enhance phagocytic activity of microglia, which is responsible for the clearance of amyloid-β (Aβ) peptides and apoptotic neurons.
- TYROBP also participates in suppression of inflammatory responses by repression of microglia-mediated cytokine production and secretion.
Why it matters
This review notes that TYROBP is upregulated in the brains of people with Alzheimer's disease and acts as a signaling adaptor for receptors including TREM2. It states that the role of TYROBP in Alzheimer's disease remains unclear and reports no treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurobiology) |
| Journal's citation record | 2 / 4 | Molecular Neurobiology: journal h-index 176 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2015 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 115 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.8 citations a year over 13 year(s) since 2015 |
| Impact for its field and year | 2 / 6 | Cited 2.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 2 / 4 | Cited 28 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jin‐Tai Yu: h-index 94 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Nanjing Medical University: institution h-index 508 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25052481) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in TREM2 and immune genetics
Also in TREM2 and immune genetics
79 studies in the library are filed under TREM2 and immune genetics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The TREM2 and immune genetics hub.